Uncommon EGFR mutations in advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.04.016
Abstract: Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the detection of actionable mutations, which has revolutionized the treatment paradigm in this highly fatal disease. Mutations involving the epidermal growth factor receptor… read more here.
Keywords: egfr; uncommon egfr; egfr mutations; lung cancer ... See more keywords
New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Respiratory Medicine"
DOI: 10.1080/17476348.2017.1267569
Abstract: ABSTRACT Introduction: Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being G719X, S768I, L861Q, and exon… read more here.
Keywords: egfr mutations; lux lung; uncommon egfr; new data ... See more keywords
PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz253.077
Abstract: Abstract Background The efficacy of immunotherapy treating EGFR-positive non-small cell lung cancer (NSCLC) patients has been proved to be limited. However, a series of mutant-patients could be benefit from PD-1 blockade. Therefore, this study evaluated… read more here.
Keywords: egfr; nsclc patients; uncommon egfr; expression ... See more keywords
Abstract 824: Uncommon EGFR mutations are associated with higher tumor mutation burden (TMB) in non-small cell lung cancer patients
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-824
Abstract: Background: Epidermal growth factor receptor (EGFR) mutation is regarded as a predictor for poor clinical response to immunotherapy in non-small cell lung cancer (NSCLC), for which common EGFR mutations (the L858R point mutation and exon… read more here.
Keywords: egfr mutations; uncommon egfr; tmb; cell ... See more keywords
Treatment outcome and functional characterization of uncommon EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9036
Abstract: 9036 Background: The nNGM centralizes molecular diagnostics, treatment recommendations and follow-up reporting in NSCLC in Germany. Uncommon EGFR mutations pose a clinical challenge because they comprise a heterogenous group and analyses of treatment outcome are… read more here.
Keywords: chemotherapy; medicine; egfr mutations; uncommon egfr ... See more keywords
NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Lung cancer"
DOI: 10.1200/jco.2022.40.16_suppl.e21076
Abstract: OBJECTIVES For refractory NSCLC patients with EGFR mutations, recent studies have demonstrated a favorable response to the combination of anti-angiogenic therapy and checkpoint inhibition but included only very few patients with uncommon EGFR mutations for… read more here.
Keywords: egfr mutations; line; chemotherapy; uncommon egfr ... See more keywords
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
Sign Up to like & getrecommendations! Published in 2019 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s181406
Abstract: Background The significance of uncommon EGFR mutations in newly diagnosed advanced non-small-cell lung cancer (NSCLC) patients is incompletely known. We aimed to analyze the demographic profile, outcome, and treatment attributes of these patients. Patients and… read more here.
Keywords: uncommon egfr; newly diagnosed; lung cancer; mutation ... See more keywords
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-0892
Abstract: Patients with uncommon EGFR-mutated non-small-cell lung cancer (NSCLC) demonstrated lower clinical efficacy of first-generation EGFR-tyrosine kinase inhibitors compared with patients harboring common EGFR-mutated NSCLC. The US FDA has approved afatinib for uncommon EGFR mutation positive… read more here.
Keywords: study; uncommon egfr; phase study; egfr mutations ... See more keywords
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.834704
Abstract: Introduction Previously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations. Methods Patients were… read more here.
Keywords: database; major uncommon; egfr mutations; activity ... See more keywords
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.919652
Abstract: Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited. Materials and… read more here.
Keywords: uncommon egfr; major uncommon; harboring major; cohort ... See more keywords
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14102519
Abstract: Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients having advanced EGFR-mutant non-small cell lung cancer (NSCLC). NSCLCs harboring… read more here.
Keywords: sensitivity; egfr tkis; egfr mutations; uncommon egfr ... See more keywords